These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30287281)

  • 1. Bispecific applications of non-immunoglobulin scaffold binders.
    Hober S; Lindbo S; Nilvebrant J
    Methods; 2019 Feb; 154():143-152. PubMed ID: 30287281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mabfilin and Fabfilin - New antibody-scaffold fusion formats for multispecific targeting concepts.
    Kahl M; Settele F; Knick P; Haupts U; Bosse-Doenecke E
    Protein Expr Purif; 2018 Sep; 149():51-65. PubMed ID: 29704557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies.
    Husain B; Ellerman D
    BioDrugs; 2018 Oct; 32(5):441-464. PubMed ID: 30132211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of CrossMAb technology for the generation of bi- and multispecific antibodies.
    Klein C; Schaefer W; Regula JT
    MAbs; 2016; 8(6):1010-20. PubMed ID: 27285945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
    Gu J; Ghayur T
    Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
    Vincent KJ; Zurini M
    Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in the Scaffold Engineering of Protein Binders.
    Ahmadi MKB; Mohammadi SA; Makvandi M; Mamouei M; Rahmati M; Dehghani H; Wood DW
    Curr Pharm Biotechnol; 2021; 22(7):878-891. PubMed ID: 32838715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats.
    Moore GL; Bernett MJ; Rashid R; Pong EW; Nguyen DT; Jacinto J; Eivazi A; Nisthal A; Diaz JE; Chu SY; Muchhal US; Desjarlais JR
    Methods; 2019 Feb; 154():38-50. PubMed ID: 30366098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.
    Liu H; Saxena A; Sidhu SS; Wu D
    Front Immunol; 2017; 8():38. PubMed ID: 28184223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering therapeutic bispecific antibodies using CrossMab technology.
    Klein C; Schaefer W; Regula JT; Dumontet C; Brinkmann U; Bacac M; Umaña P
    Methods; 2019 Feb; 154():21-31. PubMed ID: 30453028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homogeneously modified immunoglobulin domains for therapeutic application.
    Liu T; Du J; Luo X; Schultz PG; Wang F
    Curr Opin Chem Biol; 2015 Oct; 28():66-74. PubMed ID: 26117722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications.
    Steinmetz A; Vallée F; Beil C; Lange C; Baurin N; Beninga J; Capdevila C; Corvey C; Dupuy A; Ferrari P; Rak A; Wonerow P; Kruip J; Mikol V; Rao E
    MAbs; 2016 Jul; 8(5):867-78. PubMed ID: 26984268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered proteins with desired specificity: DARPins, other alternative scaffolds and bispecific IgGs.
    Jost C; Plückthun A
    Curr Opin Struct Biol; 2014 Aug; 27():102-12. PubMed ID: 25033247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Multispecific Antibodies.
    Peltret M; Schmid A; Duarte L; Mette R; Giovannini R; Bertschinger M
    Methods Mol Biol; 2024; 2810():161-180. PubMed ID: 38926279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
    Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
    J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties.
    Bezabeh B; Fleming R; Fazenbaker C; Zhong H; Coffman K; Yu XQ; Leow CC; Gibson N; Wilson S; Stover CK; Wu H; Gao C; Dimasi N
    MAbs; 2017; 9(2):240-256. PubMed ID: 27981887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineered hapten-binding antibody derivatives for modulation of pharmacokinetic properties of small molecules and targeted payload delivery.
    Dengl S; Sustmann C; Brinkmann U
    Immunol Rev; 2016 Mar; 270(1):165-77. PubMed ID: 26864111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
    Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
    Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Display scaffolds: protein engineering for novel therapeutics.
    Nuttall SD; Walsh RB
    Curr Opin Pharmacol; 2008 Oct; 8(5):609-15. PubMed ID: 18619558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity.
    Tustian AD; Endicott C; Adams B; Mattila J; Bak H
    MAbs; 2016; 8(4):828-38. PubMed ID: 26963837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.